KDR and intrahepatic cholangiocarcinoma: The agreement between the results for VEGFR2 expression in tumor tissues before anlotinib administration and the TGI of anlotinib in six ICC PDX models suggested that VEGFR2 would be a useful indicator for predicting therapeutic response to anlotinib in patients with ICC (P = 0.046, r = 0.671; Fig. S5B).